We are live on ! Find out more
ITRM

Iterum Therapeutics
ITRM

Delisted

ITRM was delisted on the 31st of March, 2026.

Back to rankings

2 hedge funds and large institutions have $542 invested in Iterum Therapeutics in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.63% less ownership

Funds ownership: 2.65% → 0.02% (-2.6%)

89% less funds holding

Funds holding: 18 → 2 (-16)

94% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 17

99% less capital invested

Capital invested by funds: $41.3K → $542 (-$40.8K)

Holders
2
Holders Change
-16
Holders Change %
-88.89%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
+$539

Top Sellers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
-$26K
2
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
-$4.16K
3
GWP
Gen-Wealth Partners
Michigan
-$2.48K
4
JF
Jump Financial
Illinois
-$2.17K
5
KF
Krilogy Financial
Missouri
-$1.74K

ITRM Hedge Fund Activity: Q2 2026 in Review

2 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Iterum Therapeutics (ITRM) for Q2 2026, worth a combined $542 — down 99% from $41.3K a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of ITRM and 1 opened new positions — a net loss of 16 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Barclays, opening a new position worth an estimated $539. The largest seller was HRT Financial, exiting entirely with an estimated $26K sold.

  • 2 institutional investors held Iterum Therapeutics (ITRM) as of Q2 2026, down from 18 in Q1 2026.
  • Funds reported $542 of Iterum Therapeutics stock for Q2 2026, down 99% quarter-over-quarter.
  • 1 fund opened new Iterum Therapeutics positions in Q2 2026 and 17 closed out, a net change of -16 holders.
  • The largest Iterum Therapeutics buyer in Q2 2026 was Barclays, an estimated $539 added.
  • The largest Iterum Therapeutics seller in Q2 2026 was HRT Financial, an estimated $26K sold.

Based on aggregated 13F filings for Q2 2026.